Matthew M. Hernandez

Matthew M. Hernandez

Auto-generated profile, based on publicly available information

Matthew M. Hernandez

Department of Pathology, Molecular, and Cell‐Based Medicine Icahn School of Medicine at Mount Sinai New York New York USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2020 in Science
Verified
Journal Article
Open access
PDF file
AGAna Silvia Gonzalez-Reiche
Ana Silvia Gonzalez-Reiche
MHMatthew M. Hernandez
Matthew M. Hernandez
MSMitchell J. Sullivan
Mitchell J. Sullivan
BCBrianne Ciferri
Brianne Ciferri
HAHala Alshammary
Hala Alshammary
HBHarm van Bakel
Harm van Bakel
Blighted Gotham: Deaths caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in New York City (NYC) during the spring of 2020 have vastly exceeded those reported in China and many other countries. What were the early events that led to such a severe outbreak? Gonzalez-Reiche et al. sampled some of the early patients seeking assistance in February and March of 2020 at the Mount Sinai Health System. Phylogenetic analysis of virus sequences in these people, who were drawn from across NYC, showed that the virus had been independently introduced many times from Europe and elsewhere in the United States. Subsequent clusters of community transmission occurred. The focus of infection in NYC is a marker of the role this city plays as a two-way hub for human movement. Science this issue p. 297

3 November 2020 in Nature
Verified
Journal Article
Closed access
PDF file
DSDaniel Stadlbauer
Daniel Stadlbauer
JTJessica Tan
Jessica Tan
KJKaijun Jiang
Kaijun Jiang
MHMatthew M. Hernandez
Matthew M. Hernandez
SFShelcie Fabre
Shelcie Fabre
Florian KrammerFlorian Krammer
Florian Krammer

1 November 2022 in Journal of Medical Virology
Verified
Journal Article
Closed access
APAlberto E. Paniz‐Mondolfi
Alberto E. Paniz‐Mondolfi
SGSusana Guerra
Susana Guerra
MMMarina Muñoz
Marina Muñoz
NLNicolas Luna
Nicolas Luna
MHMatthew M. Hernandez
Matthew M. Hernandez
JRJuan David Ramírez
Juan David Ramírez

8 May 2021 in Journal of Medical Virology
Verified
Journal Article
Open access
PDF file
MHMatthew M. Hernandez
Matthew M. Hernandez
RBRadhika Banu
Radhika Banu
PSParas Shrestha
Paras Shrestha
APArmi Patel
Armi Patel
FCFeng Chen
Feng Chen
APAlberto E. Paniz‐Mondolfi
Alberto E. Paniz‐Mondolfi
As severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) infections continue, there is a substantial need for cost‐effective and large‐scale testing that utilizes specimens that can be readily collected from both symptomatic and asymptomatic individuals in various community settings. Although multiple diagnostic methods utilize nasopharyngeal specimens, saliva specimens represent an attractive alternative as they can rapidly and safely be collected from different populations. While saliva has been described as an acceptable clinical matrix for the detection of SARS‐CoV‐2, evaluations of analytic performance across platforms for this specimen type are limited. Here, we used a novel sensitive RT‐PCR/MALDI‐TOF mass spectrometry‐based assay (Agena MassARRAY®) to detect SARS‐CoV‐2 in saliva specimens. The platform demonstrated high diagnostic sensitivity and specificity when compared to matched patient upper respiratory specimens. We also evaluated the analytical sensitivity of the platform and determined the limit of detection of the assay to be 1562.5 copies/ml. Furthermore, across the five individual target components of this assay, there was a range in analytic sensitivities for each target with the N2 target being the most sensitive. Overall, this system also demonstrated comparable performance when compared to the detection of SARS‐CoV‐2 RNA in saliva by the cobas® 6800/8800 SARS‐CoV‐2 real‐time RT‐PCR Test (Roche). Together, we demonstrate that saliva represents an appropriate matrix for SARS‐CoV‐2 detection on the novel Agena system as well as on a conventional real‐time RT‐PCR assay. We conclude that the MassARRAY® system is a sensitive and reliable platform for SARS‐CoV‐2 detection in saliva, offering scalable throughput in a large variety of clinical laboratory settings.

26 January 2022 in Journal of Virology
Verified
Journal Article
Closed access
JTJessica Tan
Jessica Tan
GOGeorge O'DEll
George O'DEll
MHMatthew M. Hernandez
Matthew M. Hernandez
ESEmilia Mia Sordillo
Emilia Mia Sordillo
ZKZenab Kahn
Zenab Kahn
MMMeagan McMahon
Meagan McMahon
The burden of influenza remains substantial despite unremitting efforts to reduce the magnitude of seasonal influenza epidemics and prepare for pandemics. Although vaccination remains the mainstay of these efforts, current vaccines are designed to stimulate an immune response against the viral hemagglutinin.

17 April 2023 in Emerging Microbes & Infections
Verified
Journal Article
Open access
LPLuz H. Patiño
Luz H. Patiño
SGSusana Guerra
Susana Guerra
MMMarina Muñoz
Marina Muñoz
NLNicolas Luna
Nicolas Luna
KFKeith Farrugia
Keith Farrugia
JRJuan David Ramírez
Juan David Ramírez
Monkeypox (MPOX) is a zoonotic disease endemic to regions of Central/Western Africa. The geographic endemicity of MPV has expanded, broadening the human-monkeypox virus interface and its potential for spillover. Since May 2022, a large multi-country MPV outbreak with no proven links to endemic countries has originated in Europe and has rapidly expanded around the globe, setting off genomic surveillance efforts. Here, we conducted a genomic analysis of 23 MPV-infected patients from New York City during the early outbreak, assessing the phylogenetic relationship of these strains against publicly available MPV genomes. Additionally, we compared the genomic sequences of clinical isolates versus culture-passaged samples from a subset of samples. Phylogenetic analysis revealed that MPV genomes included in this study cluster within the B.1 lineage (Clade IIb), with some of the samples displaying further differentiation into five different sub-lineages of B.1. Mutational analysis revealed 55 non-synonymous polymorphisms throughout the genome, with some of these mutations located in critical regions required for viral multiplication, structural and assembly functions, as well as the target region for antiviral treatment. In addition, we identified a large majority of polymorphisms associated with GA > AA and TC > TT nucleotide replacements, suggesting the action of human APOBEC3 enzyme. A comparison between clinical isolates and cell culture-passaged samples failed to reveal any difference. Our results provide a first glance at the mutational landscape of early MPV-2022 (B.1) circulating strains in NYC.